JP2025513454A5 - - Google Patents

Info

Publication number
JP2025513454A5
JP2025513454A5 JP2024562078A JP2024562078A JP2025513454A5 JP 2025513454 A5 JP2025513454 A5 JP 2025513454A5 JP 2024562078 A JP2024562078 A JP 2024562078A JP 2024562078 A JP2024562078 A JP 2024562078A JP 2025513454 A5 JP2025513454 A5 JP 2025513454A5
Authority
JP
Japan
Prior art keywords
pain
compound
alkyl
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/019478 external-priority patent/WO2023205468A1/en
Publication of JP2025513454A publication Critical patent/JP2025513454A/ja
Publication of JP2025513454A5 publication Critical patent/JP2025513454A5/ja
Pending legal-status Critical Current

Links

JP2024562078A 2022-04-22 2023-04-21 疼痛の治療のためのヘテロアリール化合物 Pending JP2025513454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263333881P 2022-04-22 2022-04-22
US63/333,881 2022-04-22
PCT/US2023/019478 WO2023205468A1 (en) 2022-04-22 2023-04-21 Heteroaryl compounds for the treatment of pain

Publications (2)

Publication Number Publication Date
JP2025513454A JP2025513454A (ja) 2025-04-24
JP2025513454A5 true JP2025513454A5 (https=) 2026-04-28

Family

ID=86382967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562078A Pending JP2025513454A (ja) 2022-04-22 2023-04-21 疼痛の治療のためのヘテロアリール化合物

Country Status (7)

Country Link
US (1) US20250388543A1 (https=)
EP (1) EP4511115A1 (https=)
JP (1) JP2025513454A (https=)
CN (1) CN119546580A (https=)
AU (1) AU2023257313A1 (https=)
CA (1) CA3256248A1 (https=)
WO (1) WO2023205468A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025256572A1 (zh) * 2024-06-13 2025-12-18 海思科医药集团股份有限公司 一种Nav1.8抑制剂及其在医药上的应用
WO2026030525A1 (en) 2024-07-31 2026-02-05 Vertex Pharmaceuticals Incorporated Zilvetrigine dosage forms and dosing regimens for treating pain

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7493493B2 (en) 2003-12-12 2009-02-17 International Business Machines Corporation Method and apparatus for password generation
AU2005266090A1 (en) 2004-07-23 2006-02-02 Pfizer Inc. Pyridine derivatives
AR063280A1 (es) 2006-10-12 2009-01-21 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
CA2748251C (en) 2008-12-26 2016-08-02 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor
CA2760946C (en) 2009-05-07 2019-06-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for studying, imaging, and treating pain
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (en) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8598164B2 (en) 2010-05-06 2013-12-03 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
MX355907B (es) 2011-02-02 2018-05-04 Vertex Pharma Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos.
JP5940562B2 (ja) 2011-02-18 2016-06-29 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
MX347982B (es) 2011-03-14 2017-05-22 Vertex Pharma Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos.
CA2830065A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
EA023375B1 (ru) 2011-10-26 2016-05-31 Пфайзер Лимитед Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
EP2788332A1 (en) 2011-12-07 2014-10-15 Amgen, Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
JP6215230B2 (ja) 2012-01-16 2017-10-18 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated イオンチャネルのモジュレーターとしてのピラン−スピロ環式ピペリジンアミド
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
WO2013131018A1 (en) 2012-03-02 2013-09-06 Zalicus Pharmaceuticals Ltd. Biaryl inhibitors of the sodium channel
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
AU2014212431B2 (en) 2013-01-31 2018-04-05 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
WO2014201173A1 (en) 2013-06-12 2014-12-18 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
ES2654393T3 (es) 2013-07-19 2018-02-13 Vertex Pharmaceuticals Incorporated Sulfonamidas como moduladores de los canales de sodio
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
EP3129381B1 (en) 2014-04-09 2020-11-04 Siteone Therapeutics Inc. 10',11'-modified saxitoxins useful for the treatment of pain
HK1248687B (en) 2015-03-02 2020-01-10 Amgen Inc. Bicyclic ketone sulfonamide compounds
US10112953B2 (en) 2015-09-30 2018-10-30 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US11279706B2 (en) 2017-03-29 2022-03-22 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
CA3058214A1 (en) 2017-03-29 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University 11,13-modified saxitoxins for the treatment of pain
US11358977B2 (en) 2017-05-16 2022-06-14 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
SG11202000230VA (en) 2017-07-11 2020-02-27 Vertex Pharma Carboxamides as modulators of sodium channels
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
AU2019302534B2 (en) 2018-07-09 2024-10-03 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8
US12162886B2 (en) 2018-10-03 2024-12-10 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2020092187A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
EP3873893A1 (en) 2018-11-02 2021-09-08 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EP3891157A4 (en) 2018-12-05 2022-08-31 Merck Sharp & Dohme Corp. 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS
CA3125244A1 (en) 2019-01-04 2020-07-09 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
JP7446316B2 (ja) 2019-01-11 2024-03-08 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換ピロリジンアミドiii
CN112996774B (zh) 2019-01-25 2022-11-22 江苏恒瑞医药股份有限公司 2-氧代-1,2-二氢吡啶类衍生物、其制备方法及其在医药上的应用
WO2020261114A1 (en) 2019-06-27 2020-12-30 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroquinazolin compounds as nav1.8 inhibitors
CN112300069A (zh) 2019-07-31 2021-02-02 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
CN112300051A (zh) 2019-07-31 2021-02-02 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
WO2021032074A1 (zh) 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
CN112441969A (zh) 2019-08-30 2021-03-05 明慧医药(上海)有限公司 一种选择性钠通道调节剂及其制备和应用
GEP20247688B (en) 2019-09-12 2024-11-11 Orion Corp Pyridine oxynitride, preparation method therefor and use thereof
CN111217776A (zh) 2020-01-19 2020-06-02 中国人民解放军军事科学院军事医学研究院 含苯并杂环结构的酰胺衍生物、组合物和应用
JP7739051B2 (ja) 2020-06-10 2025-09-16 アムジエン・インコーポレーテツド シクロブチルジヒドロキノリンスルホンアミド化合物
JP2021195367A (ja) 2020-06-10 2021-12-27 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
MX2022015857A (es) 2020-06-10 2023-01-24 Amgen Inc Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
BR112022024476A2 (pt) 2020-06-17 2022-12-27 Merck Sharp & Dohme Llc 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8
JP2023530319A (ja) 2020-06-17 2023-07-14 メルク・シャープ・アンド・ドーム・エルエルシー Nav1.8阻害剤としての2-オキソ-オキサゾリジン-5-カルボキサミド
GEP20257750B (en) 2020-06-17 2025-03-25 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
JP2023537632A (ja) 2020-08-14 2023-09-04 サイトワン セラピューティクス インコーポレイテッド 疼痛の処置のためのNaV1.7の非水和ケトン阻害剤
CN111808019B (zh) 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
WO2022121805A1 (zh) 2020-12-07 2022-06-16 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
CN112225695B (zh) 2020-12-15 2021-03-02 上海济煜医药科技有限公司 一种氮氧化合物及其制备方法和用途
CN112457294B (zh) 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
EP4334293A1 (en) 2021-05-07 2024-03-13 Merck Sharp & Dohme LLC Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
MX2023013147A (es) 2021-05-07 2023-11-28 Merck Sharp & Dohme Llc Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
TW202317520A (zh) 2021-06-15 2023-05-01 德商歌林達有限公司 經取代之吡唑醯胺

Similar Documents

Publication Publication Date Title
JP2025513454A5 (https=)
JP7770691B2 (ja) 抗ウイルス活性等の生理活性を有する化合物
CN107257803B (zh) 用于治疗细菌感染的多粘菌素类抗菌剂
JP2021534124A5 (https=)
JP2017518959A5 (https=)
RU2009102252A (ru) Хиноксалинилмакроциклические ингибиторы серинпротеазы вируса гепатита с
RU2010101611A (ru) Полициклические производные гуанина и способы их применения
RU2010126056A (ru) Органические соединения
JPWO2020123827A5 (https=)
RU2639153C2 (ru) Трициклическое бензоксабороловое соединение, способ его получения и его применение
EP2139889B1 (en) Amino-naphthyridine derivatives
WO2023129956A2 (en) Dimethyltryptamine analogues as nitric oxide delivery drugs
JP2010505865A5 (https=)
JP2013528659A5 (https=)
RU2003134629A (ru) Соединения цефема
EP1972338A1 (en) Anti-infective agents
JP7834842B2 (ja) 非対称gpr84拮抗剤およびその使用
JPWO2023066283A5 (https=)
JP2021530465A5 (https=)
CN1436173A (zh) 羟基甲脒衍生物及含有该衍生物的药物
WO2023224128A1 (ja) 線維症の治療又は予防のための医薬組成物
KR20180020119A (ko) 새로운 5형포스포디에스테라아제 억제제 및 그 용도
TWI892182B (zh) 吡唑化合物、製備方法、其醫藥組合物及其用途
CA3303518A1 (en) Compound or salt thereof and method for producing the same, pharmaceutical composition comprising the compound or salt thereof and method for producing the same
JP2007513076A5 (https=)